Abstract: The present invention relates to a bioluminescent biosensor and use of such bioluminescent biosensor for providing a generic biosensor strategy allowing direct detection of biomolecules (e.g. antibodies) or ligands (e.g. small molecules) directly in solution.

Abstract: Methods, systems, and computer storage media for providing generative artificial intelligence (AI) personalization management using a generative AI personalization engine in an item listing system. A generative AI personalization engine supports generative AI personalization management based on an automotive personalization platform including personalization training operations, personalization operations, and personalization interfaces associated with a generative AI model and an automotive domain. The generative AI personalization engine provides generative AI personalization engine operations to improve personalization and presentation of automotive-related data in an item listing system. In operation, a request associated with a user is accessed. Based on the request, automotive personalization data associated with a generative AI model is accessed.

Abstract: The present invention relates to a ratiometric bioluminescent assay for the quantification of an analyte of interest, comprising a detector luciferase that is reactive to a substrate to emit light at a first wavelength and wherein the detector luciferase is responsive to the analyte of interest and a calibrator luciferase which is reactive to the same substrate to emit light at a second wavelength which second wavelength is different from the first wavelength emitted by the detector luciferase. The invention further relates to a method for quantifying an analyte of interest in a sample using the bioluminescent assay of the present invention and wherein the quantification of the analyte of interest is based on the calibrated ratio of measured bioluminescence intensities of the detector luciferase and the calibrator luciferase. Further, the invention relates to the use of the bioluminescent assay of the present invention in a method for quantifying an analyte of interest in a sample.

Abstract: A bioluminescent biosensor and use of such bioluminescent biosensor for providing a generic biosensor strategy allowing direct detection of biomolecules (e.g. antibodies) or ligands (e.g. small molecules) directly in solution.

Abstract: A liposome for delivery of nucleic acid is provided herein, comprising cationic lipid compound, a phospholipid and a PEGylated lipid, wherein the cationic lipid compound is in an amount from 50 wt % to 90 wt % and consist of a lipid compound and a cholesterol lipid compound. A nucleic acid liposome formulation comprising the said liposome and the nucleic acid encapsulated by the liposome and the method for preparing the same are provided therein. Increased amount of nucleic acid can be loaded into the nucleic acid liposome formulation as described therein. Thus, at the same dosage, intake of the cationic lipid compound is decreased, thereby decreasing toxicity.

Abstract: A lighting device includes an elongated support member, first and second printed circuit boards, at least one first LED, at least one second LED and at least one lens element. The elongated support member includes first and second sides, the first and second PCBs coupled to the first and second sides of the elongated support member, respectively, the at least one first LED mounted on the first PCB and the at least one second LED mounted on the second PCB, each lens element includes at least one lens, the lens element mounted on the PCB at a location such that each lens substantially surrounds a respective one of the LEDs.

Abstract: An LED module having improved bonding features is described. In some embodiments, an LED module includes at least one LED light source, at least one wire, and a housing that has a rear wall having a surface. A flow channel is cut into at least one portion of the surface of the rear wall, which provides additional surface area when glue is applied to affix the housing of the LED module to a substrate.

Abstract: The present invention discloses a liposome formulation, its preparation method, and its application in the treatment of diseases caused by abnormal gene expression. The liposome formulation comprises complementary cationic lipid pairs, phospholipids, and long-circulating lipids. The method of preparing the liposome formulation comprises: mixing the complementary cationic lipid pairs with the phospholipid and the long-circulating lipid to generate pre-formed vesicles; and then mixing the pre-formed vesicles with the nucleic acid solution to generate the liposome-nucleic acid formulation. This liposome formulation provided by the present invention is easily prepared; and in the treatment of diseases caused by abnormal gene expression, the liposome formulation can be used to deliver in vivo therapeutic agents, including nucleic acids.

Abstract: A lighting device includes an elongated support member, first and second printed circuit boards, at least one first LED, at least one second LED and at least one lens element. The elongated support member includes first and second sides, the first and second PCBs coupled to the first and second sides of the elongated support member, respectively, the at least one first LED mounted on the first PCB and the at least one second LED mounted on the second PCB, each lens element includes at least one lens, the lens element mounted on the PCB at a location such that each lens substantially surrounds a respective one of the LEDs.

Abstract: An LED module is disclosed, which includes one or more LED light sources and one or more lenses. Each lens includes a lens body. The lens body includes an inner cavity having an incident surface, an emergent surface, and a reflective surface extending between the incident surface and the emergent surface for providing total internal reflection. One LED light source is situated in the inner cavity. Light emitted from the LED light source is transmitted by the incident surface. At least portion of transmitted light by the incident surface is reflected by the reflective surface to the emergent surface so as to provide a narrow light beam angle perpendicular to a length direction of the LED module. The emergent surface has a plurality of micro structures for enlarging a light viewing angle in the length direction. A sign box using one or more LED modules is also disclosed.

Abstract: An LED light module for illuminating a target plane is provided. The LED light module includes a first LED source, a second LED source disposed adjacent the first LED source, a first lens covering the first LED source, and a second lens covering the second LED source. The first lens is configured to direct first light beams emitted from the first light source to the target plane. The second lens is configured to direct second light beams emitted from the second light source to the target plane. At least one of the first and second lenses is shaped to have an asymmetrical profile. A backlighting system and a fixture incorporating the LED light module are also provided.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a biological sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (PCSK9) are disclosed. Said antagonists are effective in the inhibition of PCSK9 function and thereby provide compositions of matter useful for the treatment of conditions associated with PCSK9 activity. The present invention further discloses nucleic acids encoding PCSK9 antagonists as well as methods of making and using PCSK9 antagonists.

Abstract: Antagonists of human proprotein convertase subtilisin-kexin type 9 (“PCSK9”) are disclosed. The disclosed antagonists are effective in the inhibition of PCSK9 function and, accordingly, present desirable antagonists for use in the treatment of conditions associated with PCSK9 activity. The present invention also discloses nucleic acid encoding said antagonists, vectors, host cells, and compositions comprising the antagonists. Methods of making PCSK9-specific antagonists as well as methods of using the antagonists for inhibiting or antagonizing PCSK9 function are also disclosed and form important additional aspects of the present disclosure.

Abstract: Methods of using PCSK9 antagonists More specifically, methods for measuring circulating PCSK9 levels in a bio-logical sample by means of an immunoassay The immunoassay used can be a solid phase immunoassay, such as a dissociation-enhanced lanthanide fluorescence immunoassay utilizing an E07 capture antibody or coating and a G08 or H23 detecting antibody.